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https://doi.org/10.1186/s12889-018-5866-yRESEARCH ARTICLE Open AccessIs early measles vaccination associated with
stronger survival benefits than later
measles vaccination?
Jesper Sloth Hansen1,2, Sanne Marie Thysen1,2,3, Amabelia Rodrigues2, Cesario Martins2 and Ane Bærent Fisker1,2,4*Abstract
Background: Measles vaccine (MV) may protect against non-measles mortality. We tested whether survival
depended on age of measles vaccination.
Methods: Bandim Health Project follows children under 5 years of age through a Health and Demographic Surveillance
System in rural Guinea-Bissau. Children aged 6–36 months with a vaccination card inspected were followed to the next
visit or for a maximum of 6 months. In Cox proportional-hazards models adjusted for age and village cluster,
we compared the survival of children vaccinated with MV early (< 9 months), as recommended (9–11 months)
or late (> 12+ months) with the survival of measles-unvaccinated children. Among measles-vaccinated children, we
modelled the effect of age at measles vaccination linearly to assess mortality changes per month increase in
vaccination age.
Results: From 1999 to 2006, 14,813 children (31,725 observations) were included. Children vaccinated with MV
had a Hazard Ratio (HR) of 0.76 (95% CI: 0.63–0.91) compared with measles-unvaccinated children; censoring
measles deaths did not change the results (HR = 0.79 (0.65–0.95)). For early MV the HR was 0.68 (0.53–0.87),
for MV as recommended the HR was 0.77 (0.62–0.96) and for late MV the HR was 0.86 (0.67–1.11). Limiting
the analysis to measles-vaccinated children, age at measles vaccination was associated with a 2.6% (0.4–5.1%)
increase in mortality per month increase in vaccination age.
Conclusion: Early MV was associated with a large survival advantage. The current policy to increase
vaccination age, when measles control improves, may not optimize the impact of MV on child survival.
Keywords: Non-specific/heterologous effects of vaccines, Measles vaccine, Childhood mortalityBackground
Vaccination policies are based on the assumption that a
vaccine only protects against the targeted disease. New
knowledge indicates that this perception should be re-
vised: Vaccines may affect the overall mortality and mor-
bidity through training of the immune system. In other
words, vaccines seem to have non-specific effects (NSEs)
altering susceptibility to non-targeted infections [1].
WHO recently reviewed the evidence for NSEs of
the Bacillus Calmette-Guérin vaccine (BCG),
diphtheria-tetanus-pertussis vaccine (DTP) and measles* Correspondence: abf@ssi.dk
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(http://creativecommons.org/publicdomain/zevaccine (MV) [2]. For MV, the review concluded that the
evidence was consistent with beneficial NSEs, which were
stronger for girls than for boys [3]. Current vaccination pol-
icies do not take the NSEs into account. WHO recom-
mends MV at 9 months of age in countries with a high
burden of measles [4]. In areas where measles infection is
controlled, MV is recommended at 12 months of age. Mea-
sles vaccination in the presence of maternal measles anti-
bodies (MatAb) reduces the antibody response [5, 6] and
delaying vaccination until MatAb have waned optimizes
seroconversion [4]. Hence, the recommendation of MV at
9 months of age in low-income countries is a compromise
between ensuring protection against measles infection early
in life and minimizing interference from MatAb [4].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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dose of MV at 4.5 months in addition to the routine
MV at 9 months of age compared with the standard
dose of MV at 9 months reduced mortality between
4.5 and 36 months of age (hazard ratio (HR) 0.70
(95% CI: 0.52–0.94)) [7]. In a subgroup of children
for whom MatAb were assessed before vaccination at
4.5 months, the HR between 4.5 and 5 years of age
was 0.29 (0.09–0.91) for children with MatAb com-
pared with children without MatAb at time of mea-
sles vaccination [8]. Therefore vaccinating earlier and
providing MV in the presence of MatAb may modu-
late the immune system in a beneficial way resulting
in better child survival [8, 9]. This is supported by a
recent review indicating better survival for children
vaccinated before 12 months of age than for children
vaccinated after 12 months of age [10].
Though the WHO-recommended age of MV is
9 months, many children in Guinea-Bissau receive MV
before that age. We evaluated, whether MV given before
9 months of age was associated with stronger survival
advantage than MV given after 9 or 12 months of age.Methods
Setting and study population
Bandim Health Project (BHP) has conducted research
based on a Health and Demographic Surveillance System
(HDSS) in Guinea-Bissau for 39 years. The rural HDSS
was established in 1990, covering 20 clusters of 100
women in each of the five most populous regions in
Guinea-Bissau. Women of fertile age and their children
are followed through home visits in the villages every 6
months. At all visits, pregnancies are registered and in-
formation on vital status, vaccination status and nutri-
tional status is recorded for children up to 5 years of
age. For children who died since the previous visits, the
respondent is asked to state the date and cause of death.
Furthermore, we register all new women and note their
ethnicity, years of schooling and age.
Data for the present study were collected between
January 1st 1999, just after a civil war, and May 15th
2006, when a national MV campaign started [11]. Chil-
dren aged 6 to 36 months of age were eligible for the
study. The vaccination program in Guinea-Bissau was
BCG and oral polio vaccine (OPV) at birth and three
doses of OPV and DTP vaccine at 6, 10 and 14 weeks of
age. MV was scheduled at 9 months of age and booster
doses of DTP and OPV were recommended at
18 months.
In addition to the routine vaccination program, 14
campaigns distributing MV, OPV and vitamin A supple-
mentation (VAS) took place in Guinea-Bissau during the
study period (Additional file 1: Table S1).Assessment of vaccination status and nutritional status
At all home visits, field assistants registered whether
they had seen the vaccination card and if seen copied
the vaccination dates. Children who possessed, but did
not present a vaccination card could only enter at a later
visit if the card was seen. Children were considered
measles-unvaccinated if they presented a vaccination
card without a MV registered or if they did not have a
vaccination card and the mother stated that the child
had never been vaccinated. Nutritional status was
assessed by measurement of the mid-upper-arm circum-
ference (MUAC). The mothers were asked about breast-
feeding and supplementary feeding.
Statistical analyses
We compared background information for measles-vaccinated
children and measles-unvaccinated children included
in the analysis using the Wilcoxon rank-sum test,
χ2-test and t-test. The child MUAC is presented as
z-score compared to the WHO reference [12].
We compared overall mortality between measles-vaccinated
children and measles-unvaccinated children in Cox
proportional hazards models with age as underlying
time and stratified by cluster. Children entered the
analysis on the date their vaccination card was
inspected and remained under follow-up until the
subsequent visit (when information on vital status
was obtained) or for a maximum of 6 months. Thus,
a child could contribute several, not overlapping ob-
servation periods with known vaccination status at
the beginning of the period, while observation periods
with unknown vaccination status at the beginning of
the interval, were excluded. To asses at what age it
was most beneficial to receive MV, measles-vaccinated
children were divided in three groups according to
their age at measles vaccination: Early (6–8 months
(<=274 days)), recommended (9–11 months (275–
365 days)) and late (> 11 months (> = 366 days)).
Three percent of measles-vaccinated children (330/
11,260) had a measles vaccination age before
6 months. These children were classified as vacci-
nated at 6 months in the analyses. Each child could
contribute with several observations at different time
points in the unvaccinated or the vaccinated groups
according to the vaccination status at the beginning
of the follow-up period. Since several studies have
found sex-differential effects of MV [3, 9, 13–15], we
stratified the analyses by sex. The results are pre-
sented as mortality rates (deaths per 1000 person
years (PYRS)) and HRs with 95% confidence intervals.
All background factors (Table 1) were included as co-
variates in the Cox model one by one to see if they
altered the estimates by more than 10%. No estimate
changed by more than 6% (Additional file 1: Table S2),
Table 1 Characteristics at the beginning of an observation period
Measles unvaccinated Measles Vaccinated P-value
Number (%) 9440 (30) 22,285 (70)
Agea [median (IQR)] 10.9 (8.1–17.6) 22.6 (16.3–28.9) <.0001
Sex [n (%)] 0.68
Male 4782 (51) 11,345 (51)
Child MUAC (z-score)b [mean (SD)] −0.60 (1.15) −0.66 (1.07) <.0001
Region [n (%)] <.0001
Oio 1930 (30) 4477 (70)
Biombo 2287 (34) 4438 (66)
Gabu 1685 (24) 5352 (76)
Cacheu 1613 (31) 3524 (69)
Bafata 1925 (30) 4494 (70)
Ethnicity [n (%)]c <.0001
Balanta 1701 (18) 3159 (14)
Papel 1904 (20) 3587 (16)
Mandinga, Fula 4419 (47) 12,268 (55)
Mandjaco, mancanha 789 (8) 1615 (7)
Others 578 (6) 1519 (7)
Season of birth [n (%)] .0008
Dry season 5215 (55) 12,770 (57)
Maternal schooling [n (%)]d 0.08
0 years 6277 (66) 15,450 (69)
1–4 years 1111 (12) 2522 (11)
> 4 years 419 (4) 964 (4)
Maternal agee [mean(SD)] 26.1 (6.9) 25.9 (6.9) 0.01
Maternal MUACf [mean [SD]] 254 (25) 256 (1.07) <.0001
Lives with motherg [n (%)] <.0001
Yes 9352 (99) 21,983 (99)
No 73 (1) 293 (1)
Stopped breastfeedingh [n (%)] <.0001
Yes 1116 (12) 8976 (40)
No 8318 (88) 13,304 (60)
Sleeping under a bed neti [n (%)] 0.13
All year 3644 (39) 8882 (40)
Rainy season only 5496 (58) 12,736 (57)
No 280 (3) 645 (3)
Year of card inspection [n (%)] <.0001
1999 1002 (11) 2283 (10)
2000 1202 (13) 2621 (12)
2001 1528 (16) 2766 (12)
2002 1524 (16) 2717 (12)
2003 1165 (12) 3186 (14)
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Table 1 Characteristics at the beginning of an observation period (Continued)
Measles unvaccinated Measles Vaccinated P-value
2004 1113 (12) 3564 (16)
2005 1373 (15) 3614 (16)
2006 533 (6) 1535 (7)
aAge in months at the date of card inspection
bMean Z-score MUAC-for-age using the 2006 WHO reference (Standard deviation). Missing information for 550 observations from measles-unvaccinated and
children and 988 observations from measles-vaccinated children
cMissing information for 49 observations from measles-unvaccinated children and 137 observations from measles-vaccinated children
dMissing information for 1633 observations from measles-unvaccinated children and 3351 observations from measles-vaccinated children
eMean maternal age at the date of the child’s birth (Standard deviation). Missing information for 50 observations from measles-unvaccinated children and 130
observations from measles-vaccinated children
fMean maternal MUAC at registration of pregnancy (Standard deviation). Missing information for 5576 observations from measles-unvaccinated children and
12,731 observations from measles-vaccinated children
gMissing information for 4 observations from measles-unvaccinated children and 3 observations from measles-vaccinated children
hMissing information for 5 observations from measles-unvaccinated children and 5 observations from measles-vaccinated children
iMissing information for 19 observations from measles-unvaccinated children and 22 observations from measles-vaccinated children
Abbreviations: MUAC mid-upper-arm-circumference
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estimates. Among measles-vaccinated children, we
modelled measles vaccination age as a continuous
variable. Modelling the age at vaccination as a linear
spline with four knots did not describe the data any
better than the simple linear model (Likelihood Ratio
test, p = 0.29) and we therefore describe mortality
changes per month increase in measles vaccination
age across the whole age span.
To disentangle the effect of early MV from the effect of
campaigns with other vaccines or VAS, we conducted sur-
vival analyses in which follow-up time was split on the first
day of the national campaigns. Since campaigns in
Guinea-Bissau have had very high coverage [16], we did not
rely on individual level information but split follow-up
time at the time a child was eligible for a campaign.
All children contribute observation time in the
pre-campaign group until the date of the campaign
and time in the after-campaign group after the split.
We used Stata14 for the analyses.Results
Study population
Between January 1st 1999 and May 15th 2006, BHP
followed 20,701 children between 6 and 36 months of
age in rural Guinea-Bissau of whom 14,823 (72%) had a
vaccination card inspected. Excluding 10 children with
unknown MV date, we retained 14,813 children contrib-
uting 31,725 observations in the analyses (Fig. 1). MV
coverage increased with age, being 8% (296/3568) for
children when they had their vaccination card seen be-
tween 6 and 8 months of age, 46% (1671/3660) for chil-
dren when their card was inspected between 9 and
11 months and 77% (9898/12,825) when their card was
first inspected between 12 and 36 months. Overall, chil-
dren were measles vaccinated at 70% (22,285/31,725) of
the observations (Fig. 1).Baseline characteristics
The observations from measles-unvaccinated children
came from younger children (median age 10.9 months)
than the observations from measles-vaccinated children
(median age 22.6 months) (p < 0.0001). MUAC-for-age
was lower for the measles-vaccinated than for the
measles-unvaccinated children, but this difference disap-
peared when the comparison was stratified by age group
(Additional file 1: Table S3). The proportion of
measles-vaccinated children differed by region (p < 0.0001)
and ethnicity (p < 0.0001). Furthermore, there were slight
differences by season of birth (p = 0.0008), maternal
age (p = 0.01) and maternal MUAC during pregnancy
(p < 0.0001). Sex, sleeping under mosquito net and
maternal schooling did not differ significantly between
the two groups (Table 1, Additional file 1: Table S3).
Mortality
Among all measles-vaccinated children, 23% (2560 chil-
dren; 5740 observations) were vaccinated before 274 days
of age, 43% (4846 children; 9706 observations) between
274 and 365 days of age and 34% (3854 children; 6839
observations) after 365 days of age (Table 2). The mor-
tality rate was 45/1000 PYRS among measles-vaccinated
children overall (Early-vaccinated: 42/1000 PYRS,
recommended age: 44/1000 PYRS and late vaccinated:
48/1000 PYRS), whereas it was 66 among
measles-unvaccinated children (Table 2). In spite of al-
most half of the measles-unvaccinated children receiving
MV during follow-up (Table 2, Additional file 1), mortal-
ity among measles-vaccinated children was lower than
among measles-unvaccinated children (HR 0.76 (95% CI:
0.63–0.91)). The difference in survival between
measles-vaccinated and measles-unvaccinated children
was statistically significant for early-vaccinated children
(HR: 0.68 (0.53–0.87)) and children vaccinated at the
recommended age (HR: 0.77 (0.62–0.96)), but not for
late-vaccinated children (HR: 0.86 (0.67–1.11)) (Table 2).
Fig. 1 Flowchart illustrating study population
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the conclusion (Additional file 1: Table S4).
Limiting the analysis to the measles-vaccinated chil-
dren and modelling the effect of MV-age linearly, mor-
tality was 2.6% (0.4–5.1%) higher for each month the
measles vaccination age increased.
Stratified by sex, measles-vaccinated children had
lower mortality for both boys (HR = 0.79 (0.62–1.00))
and girls (HR = 0.73 (0.57–0.93), Table 2). The pattern of
better survival with lower age at MV was evident for
girls, the estimates being 0.57 (0.40–0.81) for early vac-
cination, 0.79 (0.59–1.05) for children vaccinated at 9–
11 months and 0.83 (0.60–1.15) for children vaccinated
after 12 months of age. The age of MV seemed of less im-
portance in boys (Table 2), but we saw no evidence of an
interaction between sex and age of MV when limiting the
analysis to measles-vaccinated children (p = 0.93). Mortal-
ity tended to be lower for girls than boys among
early-vaccinated children (Additional file 1).
Campaign analyses
When observation time was split at the date of the first
OPV campaign after inspecting the vaccination card,
31% of observation time was after OPV campaigns.
Lower age at vaccination was associated with lower mor-
tality before OPV campaigns, but less consistently so
after OPV (Table 3). For the VAS campaigns, 27% of ob-
servation time was after campaigns. The pattern for theeffect of age of MV was similar before and after VAS
campaigns and the mortality did not differ significantly
before and after the campaign (p = 0.34 for interaction
between VAS campaign and vaccination status). The es-
timates were similar for boys and girls (Table 3, p = 0.86
for interaction between sex, VAS and MV status). Only
2–5% of children were exposed to the MV or meningitis
campaigns and data were insufficient to assess the effect
of age of MV after the meningitis and MV campaigns.
Censoring at the MV and meningitis campaigns did not
alter the conclusions (Additional file 1: Table S5).
Discussion
Main results
Measles-vaccinated children had a significantly lower
mortality compared with measles-unvaccinated children.
The benefit was stronger for early-vaccinated children.
Strengths and weaknesses
The study was conducted within a well-established
HDSS representative of the rural population of
Guinea-Bissau. The data were collected from the five
most populous regions in Guinea-Bissau, where a large
cohort of over 14,000 children contributing more than
30,000 observations was followed. The data collection in
the rural areas had been ongoing for 9 years at the initi-
ation of the study, and the field workers were
experienced.
Table 2 Mortality for children with and without measles vaccine and vaccines during follow-up. Stratified by age at measles
vaccination and sex
Number of
observations
MR per 1000 PYRS
(deaths/PYRS)
HR (95% CI)a Number of observations
with a seen vaccination
card within 12 months
after visit
Measles Vaccinated
during follow up
DTP Vaccinated
during follow up
All children
Measles unvaccinated 9440 65.5 (272/4155) 1 (ref) 5825 48% (2767/5825) 30% (1721/5825)
Measles vaccinated 22,285 44.9 (441/9811) 0.76 (0.63–0.91) 16,535 3% (532/16535) 10% (1580/16535)
Early age (< 274 days)b 5740 41.9 (106/2528) 0.68 (0.53–0.87) 4096 4% (183/4096) 10% (424/4096)
Recommended age
(274–365 days) b
9706 44.3 (188/4245) 0.77 (0.62–0.96) 7027 3% (201/7027) 7% (489/7027)
Late (366–735 days) b 6839 48.4 (147/3038) 0.86 (0.67–1.11) 5412 3% (148/5412) 12% (667/5412)
Boys
Measles unvaccinated 4782 63.7 (134/2104) 1 (ref) 2943 47% (1385/2943) 28% (832/2943)
Measles vaccinated 11,345 46.2 (231/4995) 0.79 (0.62–1.00) 8505 3% (270/8505) 10% (814/8505)
Early age (< 274 days) b 2936 48.1 (62/1290) 0.79 (0.57–1.08) 2074 4% (85/2074) 11% (228/2074)
Recommended age
(274–365 days)b
4959 42.8 (93/2170) 0.75 (0.56–1.00) 3636 3% (107/3636) 7% (254/3636)
Late (366–735 days)b 3450 49.5 (76/1535) 0.89 (0.64–1.22) 2795 3% (78/2795) 12% (332/2795)
Girls
Measles unvaccinated 4658 67.3 (138/2051) 1 (ref) 2882 48% (1382/2882) 31% (889/2882)
Measles vaccinated 10,940 43.6 (210/4816) 0.73 (0.57–0.93) 8030 3% (262/8030) 10% (766/8030)
Early age (< 274 days)b 2804 35.5 (44/1238) 0.57 (0.40–0.81) 2022 5% (98/2022) 10% (196/2022)
Recommended age
(274–365 days)b
4747 45.8 (95/2075) 0.79 (0.59–1.05) 3391 3% (94/3391) 7% (235/3391)
Late (366–735 days)b 3389 47.2 (71/1503) 0.83 (0.60–1.15) 2617 3% (70/2617) 13% (335/2617)
aAge as underlying time scale, stratified by village cluster; bAge at measles vaccination according to the information obtained from the vaccination card at the
beginning of the observation period. Abbreviations: MR Mortality Rate, PYRS Person years, HR Hazard Ratio, CI Confidence interval
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entered the analyses after vaccination status was
assessed by inspecting a vaccination card. Hence, the
measles-unvaccinated group was well defined. Fur-
thermore, children could only change vaccination sta-
tus from the date of seeing a vaccination card. This
method eliminates the risk of survival bias but mis-
classifies some observation time for children vacci-
nated between two visits and therefore provides
conservative estimates [17].
Receiving MV during follow-up could lead to bias
in the estimated association between age of MV and
mortality. Among the measles-vaccinated children,
only 3% received a second dose of MV during
follow-up and 10% received DTP, while more
measles-unvaccinated children received MV (48%) and
DTP (30%) during follow-up. However, the effect of
age at vaccination remained evident when the analysis
was limited to measles-vaccinated children, among
whom few were vaccinated during follow-up.
The two groups differ with regard to many of the
measured baseline characteristics. As with all observa-
tional studies, we cannot exclude confounding.However, adjusting for measured background factors
did not alter the estimates by more than 6%. Further-
more, since the analyses were stratified by cluster and
had age as underlying timescale, we only compared
mortality of measles-vaccinated children with
measles-unvaccinated children within the same village
and of the same age. Therefore, the children com-
pared are more similar than children from different
villages, which may explain why adjusting for the
background factors had little effect.
The cause of death classifications are based on mater-
nal information. However, we presume that the data on
deaths due to measles, a well-known and characteristic
infection, are accurate. Frailty bias could occur in the
study with sick children not being vaccinated and hence
an increasingly frail group of unvaccinated children the
longer after the recommended age of MV the vaccin-
ation cards were inspected. Reasons for not being vacci-
nated were not registered. However, if the differential
survival was caused by frailty bias, the estimated effect
of MV compared with unvaccinated should be weakened
by adjusting for MUAC at the time of card inspection,
which it did not (Supplementary Table 2). Furthermore,
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(as the unvaccinated children become an increasingly se-
lected group). This was not the case; on the contrary,
the differential survival was stronger in the younger chil-
dren, indicating that it was not a frail subgroup, which
did not receive MV.Consistency with previous studies
Several studies have indicated stronger beneficial effects
of MV in girls than in boys [9, 13–15], as also concluded
in the WHO review [3]. In our study, the effect may
have been slightly stronger for girls than for boys. The
WHO review did not conclude on the importance of age
at vaccination, stating that the evidence was insufficient
[3]. However, a number of studies have assessed the im-
pact of age at vaccination. In line with our results, a re-
view of data published until 2015 also revealed that early
MV is more beneficial than later MV [10]. In a study
from 1993, children receiving MV at 4–8 months had
lower mortality than children vaccinated later. This
could partly be explained by the early-vaccinated chil-
dren being revaccinated. In our study, revaccination oc-
curred in only 4% of early-vaccinated children and 3% of
late-vaccinated children during follow-up. Hence, it is
unlikely that the beneficial effects of early MV are ex-
plained by revaccination. There were few deaths after
MV campaigns and we could therefore not evaluate
whether the effect of early MV differed before and after
the campaign.
Previous studies have indicated a beneficial effect of
VAS campaigns with or after MV, but not of VAS with
or after DTP. In an observational study of VAS cam-
paigns, where vaccination status was documented, VAS
was beneficial when MV was the most recent vaccine
(HR for VAS vs. no-VAS = 0.34 (0.14–0.85)), while VAS
was not associated with lower mortality when DTP was
the most recent vaccine (HR = 1.29 (0.52–3.22)) [18]. In
a campaign, where VAS was co-delivered with missing
vaccines, children who had received VAS and DTP had
higher mortality than children who had received VAS
and MV simultaneously (p for homogeneity = 0.0005)
[19]. In our study, we did not find any difference in the
effect of age at MV before and after the VAS cam-
paign. Nor did we see a sex-differential effect of VAS
campaigns. In a randomized controlled trial of VAS
at vaccination contacts, where 63% received VAS or
placebo with MV, we found that VAS was beneficial
for girls (HR = 0.45 (0.24–0.87), but not for boys
(HR = 1.92 (0.98–3.75) [20]. Whether the contrasting
effects should be explained by timing of the interven-
tions relative to each other, or possibly co-delivered
interventions (i.e. OPV) should be studied in more
detail.Interpretation and implications
Our study suggests that early MV lowers mortality, but giv-
ing early MV is only recommended under special circum-
stances [21] to avoid interference from MatAb on the
antibody response to MV [4]. In a randomized trial, a
two-dose vaccination strategy with MV at 4½ and 9 months
vs. one dose at 9 months resulted in lower antibody titer at
24 months of age, but 97% still obtained protective anti-
body levels [22]. However, though the antibody response
may be blunted, MV given in presence of MatAb still pre-
vents measles, especially severe measles and measles mor-
tality [23]. Hence, the sole focus on measles antibodies as
marker of the effect of MV may obstruct the best use of
the vaccine. The policy should be based on the impact of
early MV on child health: If early MV in the presence of
MatAb lowers mortality, as the present data and a previous
study from Guinea-Bissau indicate [8], and does not impair
protection against measles [23], early MV should be policy.
The current policy is that the age of MV should increase
when measles infection is under control. Our study sug-
gests that this may lead to increased overall child mortal-
ity. Children will not benefit from the beneficial NSEs at a
younger age and will not benefit from the additional NSEs
of early MV. In contrast, it might decrease mortality fur-
ther, if an early first dose followed by a second booster
dose around 9 months of age was introduced. However,
further assessment of the effect of early MV is needed.Conclusion
Measles-vaccinated children had a significantly better
survival compared with measles-unvaccinated chil-
dren, the beneficial effects being strongest for
early-vaccinated children. Given the beneficial effects
of MV, the current policy to increase the age of vac-
cination when measles control improves may not
optimize the impact of MV on mortality. The benefi-
cial NSEs of MV and the differential effect of MV by
age at vaccination should be considered when plan-
ning vaccination programs in low-income countries.Additional file
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